Table 1. Ongoing clinical trials in youth with type 2 diabetes

NCT	Phase	Drug (route)	Categories	Age of participants
05260021	III	Tirzepatide (weekly SC)	GLP-1 analog	10–18 years (child, adult)
04596631	III	Semaglutide (oral)	GLP-1 analog	10–17 years (child)
04029480	III	Ertugliflozin (oral)	SGLT2 inhibitors	10–17 years (child)
03170518	III	Canagliflozin (oral)	SGLT2 inhibitors	10–17 years (child)
03199053	III	Dapagliflozin, Saxagliptin (oral)	DPP-4 inhibitors	10–18 years (child, adult)
03429543	III	Linagliptin, Empagliflozin (oral)	DPP-4 inhibitors	10–17 years (child)

The National Clinical Trial (NCT) numbers denote ClinicalTrial.gov identifiers.
SC, subcutaneous; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose transporter-2; DPP-4, dipeptidyl peptidase-4.